ASX Announcement

Results of Annual General Meeting

24 November 2022 – Race Oncology Limited (**Race** or the **Company**) (ASX: RAC) advises that its Annual General Meeting of Shareholders was held today at 12.00 pm (AEDT).

The resolutions were voted in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange, with all resolutions being passed on a poll.

Resolution 3 (Replacement of Constitution) was passed by a sufficient majority as a special resolution.

Further information required by section 251AA(2) of the Corporations Act 2001 (Cth) is attached.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target breast cancer.

The Company also has compelling clinical data for Zantrene as a chemotherapeutic agent and is in multiple clinical trials in Acute Myeloid Leukaemia (AML).

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Zantrene. Learn more at www.raceoncology.com

Release authorised by:

Phil Lynch, CEO/MD on behalf

of the Race Board of Directors

phillip.lynch@raceoncology.com

Media contact:

Jane Lowe

+61 411 117 774

jane.lowe@irdepartment.com.au

Disclosure of Proxy Votes

Race Oncology Limited

Annual General Meeting

Thursday, 24 November 2022

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)		
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**Total Number of Proxy Votes exercisable by proxies validly appointed**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**
1 Adoption of Remuneration Report	P	17,015,749	16,188,081 95.14%	44,468 0.26%	57,637	783,200 4.60%	25,330,017 99.82%	44,468 0.18%	116,502
2 Re-Election of Director – Dr John Edward Cullity	P	23,203,783	21,459,638 92.48%	979,805 4.22%	2,400,946	764,340 3.29%	44,743,964 97.75%	1,030,615 2.25%	2,501,397
3 Replacement of Constitution	P	25,595,486	24,736,731 96.64%	59,343 0.23%	9,243	799,412 3.12%	48,091,154 99.88%	59,343 0.12%	125,479